Drugs / CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
Cell therapy targets CD33, CD38, IL3RA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05995041 | Jun 2026 → Dec 2029 expected | acute myeloid leukemia | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05995041 ↗ |
| Modality | Cell therapy | “universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123” NCT05995041 ↗ |
| Target | CD123 | “universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123” NCT05995041 ↗ |
| Target | CD33 | “universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123” NCT05995041 ↗ |
| Target | CD38 | “universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123” NCT05995041 ↗ |